Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global endometrial cancer therapeutics market. The report identifies the key trends shaping and driving the global endometrial cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometrial cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated has estimated the global endometrial cancer market to be valued at $137 m in 2010. It is expected to grow to $179 m with a Compound Annual Growth Rate (CAGR) of 3.91% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to the aging population, diabetes and obesity. The diagnosis and treatment seeking rate is also high in endometrial cancer. Currently there are no approved drugs for endometrial cancer and the market will be driven by the expected launch of the Ixempra (ixabepilone) in 2015.

Scope

The report provides information on the key drivers and challenges of the endometrial cancer therapeutics market. Its scope includes -

• Annualized seven key markets (The US, France, Germany, Italy, Spain, The UK and Japan) endometrial cancer market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under the following mechanism of action which are LHRH antagonists, mTOR inhibitor, angiogenesis inhibitor, VEGF inhibitor, TK inhibitor and DNA Repair Suppressor, AKT/PKB inhibitor, LH/hCG targeter, MEK inhibitor and AKT kinase inhibitor, steroid sulphatase inhibitor, tubulin-binding agent, beta-catenin targeter, mTOR kinase inhibitor and AKT inhibitor, triple angiokinase inhibitor and cytotoxic agent
• Analysis of the current and future competition in the seven key countries endometrial cancer market. Key market players covered are AEterna Zentaris, Bristol-Myers Squibb Company, Eisai Co., EntreMed, Novartis AG, and PharmaMar,
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the endometrial cancer therapeutics market.
• Analysis of key recent licensing and partnership agreements in endometrial cancer market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global endometrial cancer market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global endometrial cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global endometrial cancer market landscape? - Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ENDOMETRIAL CANCER THERAPEUTICS: INTRODUCTION

2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.5 Diagnosis
2.6 Prognosis
2.7 Pathology
2.8 Staging
2.9 Treatment
2.10 GlobalData Pipeline Report Guidance

3 ENDOMETRIAL CANCER THERAPEUTICS: MARKET CHARACTERIZATION

3.1 Endometrial Cancer Therapeutics Market Size (2005-2010) – Global
3.2 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Global
3.3 Endometrial Cancer Therapeutics Market Size (2005-2010) – The US
3.4 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – The US
3.5 Endometrial Cancer Therapeutics Market Size (2005-2010) – France
3.6 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – France
3.7 Endometrial Cancer Therapeutics Market Size (2005-2010) – Germany
3.8 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Germany
3.9 Endometrial Cancer Therapeutics Market Size (2005-2010) – Italy
3.10 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Italy
3.11 Endometrial Cancer Therapeutics Market Size (2005-2010) – Spain
3.12 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Spain
3.13 Endometrial Cancer Therapeutics Market Size (2005-2010) – The UK
3.14 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – The UK
3.15 Endometrial Cancer Therapeutics Market Size (2005-2010) – Japan
3.16 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers
  3.17.1 Drivers for the Endometrial Cancer Therapeutics Market
  3.17.2 Barriers for the Endometrial Cancer Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 ENDOMETRIAL CANCER THERAPEUTICS: COMPETITIVE ASSESSMENT

4.1 Overview
  4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Marketed Products in the Endometrial Cancer Therapeutics Market
  4.2.1 Carboplatin plus Paclitaxel
  4.2.2 Cisplatin Plus Doxorubicin
  4.2.3 Cisplatin + Doxorubicin + Paclitaxel
  4.2.4 Liposomal doxorubicin
  4.2.5 Hormone therapies
4.3 Key Takeaway

5 ENDOMETRIAL CANCER THERAPEUTICS: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Endometrial Cancer Therapeutics Pipeline – Pipeline by Clinical Phases of Development
5.4 Pipeline Analysis by Phase of Development
  5.4.1 Endometrial Cancer Therapeutics – Phase III Pipeline
  5.4.2 Endometrial Cancer Therapeutics – Phase II Pipeline
  5.4.3 Endometrial Cancer Therapeutics – Phase I Pipeline
  5.4.4 Endometrial Cancer Therapeutics – Preclinical Pipeline
5.5 Technology Trends Analytical Framework
5.6 Pipeline by Mechanism of Action
5.7 Endometrial Cancer Therapeutics – Promising Drugs Under Clinical Development
5.8 Molecule Profile for Promising Drugs Under Clinical Development
  5.8.1 Ixempra
5.9 Key Takeaway

6 ENDOMETRIAL CANCER THERAPEUTICS: CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Therapeutics Clinical Trials

7 ENDOMETRIAL CANCER THERAPEUTICS: STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Endometrial Cancer Therapeutics – Implications for Future Market Competition

8 ENDOMETRIAL CANCER THERAPEUTICS: FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Bristol-Myers Squibb Company
  8.2.2 AEterna Zentaris Inc
  8.2.3 Ariad Pharmaceuticals Inc
  8.2.4 Eisai Co., Ltd
  8.2.5 EntreMed, Inc.
  8.2.6 Exelixis, Inc.
  8.2.7 Ipsen S.A. (Ipsen)
  8.2.8 Merck & Co
  8.2.9 Novartis AG
  8.2.10 PharmaMar, S.A (Subsidiary of Zeltia, S.A.)
  8.2.11 Sanofi
8.3 Details of Other Companies in the Pipeline

9 ENDOMETRIAL CANCER THERAPEUTICS: DEALS

10 ENDOMETRIAL CANCER THERAPEUTICS: APPENDIX

10.1 Market Definitions
10.2 Appendix
10.3 Research Methodology
  10.3.1 Coverage
  10.3.2 Secondary Research
  10.3.3 Forecasting
  10.3.4 Primary Research
  10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: Endometrial Cancer Staging – TNM Classification
Table 2: Endometrial Cancer – Staging Terminology
Table 3: Endometrial Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 4: Endometrial Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: Endometrial Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010
Table 6: Endometrial Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017
Table 7: Endometrial Cancer Therapeutics Market, France, Revenue ($m), 2005–2010
Table 8: Endometrial Cancer Therapeutics Market, France, Forecast ($m), 2010–2017
Table 9: Endometrial Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 10: Endometrial Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017
Table 11: Endometrial Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 12: Endometrial Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017
Table 13: Endometrial Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 14: Endometrial Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017
Table 15: Endometrial Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010
Table 16: Endometrial Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017
Table 17: Endometrial Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 18: Endometrial Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017
Table 19: Endometrial Cancer Therapeutics – Phase III Pipeline, 2011
Table 20: Endometrial Cancer Therapeutics – Phase II Pipeline, 2011
Table 21: Endometrial Cancer Therapeutics – Phase I Pipeline, 2011
Table 22: Endometrial Cancer Therapeutics – Preclinical Pipeline, 2011
Table 23: Endometrial Cancer Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 24: Endometrial Cancer Therapeutics – Clinical Trials by Country, 2011
Table 25: Endometrial Cancer Therapeutics – Clinical Trials by Phase, 2011
Table 26: Endometrial Cancer Therapeutics – Clinical Trials by Status, 2011
Table 27: Endometrial Cancer Therapeutics – Prominent Sponsors, 2011
Table 28: Endometrial Cancer Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 29: Bristol-Myers Squibb Company, Pipeline, 2011
Table 30: Bristol-Myers Squibb Company Deals, 2009-2010
Table 31: AEterna Zentaris Inc, Oncology Pipeline, 2011
Table 32: AEterna Zentaris, Deals, 2009-2010
Table 33: Ariad Pharmaceuticals Inc, Oncology Pipeline, 2011
Table 34: Ariad Pharmaceuticals Inc, Deals, 2009-2010
Table 35: Eisai Co. Ltd, Oncology Pipeline, 2011
Table 36: Eisai Co. Ltd, Deals, 2009-2011
Table 37: EntreMed Inc, Oncology Pipeline, 2011
Table 38: EntreMed Inc, Deals, 2010
Table 39: Exelixis Inc., Pipeline, 2011
Table 40: Exelixis Inc., Deals, 2009-2010
Table 41: Ipsen S.A, Pipeline, 2011
Table 42: Ipsen S.A, Deals, 2009-2010
Table 43: Merck & Co., Inc, Oncology Pipeline, 2011
Table 44: Merck & Co., Inc, Deals, 2009-2011
Table 45: Novartis – Oncology Pipeline, 2011
Table 46: Novartis AG, Deals ,2009-2010
Table 47: PharmaMar, S.A, Deals, 2009
Table 48: Sanofi Oncology Pipeline, 2011
Table 49: Sanofi Key Deals, 2010-2011
Table 50: Details of Other Companies in the Pipeline
Table 51: Endometrial Cancer Therapeutics, Global, Deals, 2010

LIST OF FIGURES

Figure 1: Endometrial Cancer – Surgical Procedures
Figure 2: Endometrial Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 3: Endometrial Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 4: Endometrial Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010
Figure 5: Endometrial Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017
Figure 6: Endometrial Cancer Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 7: Endometrial Cancer Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 8: Endometrial Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 9: Endometrial Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 10: Endometrial Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 11: Endometrial Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 12: Endometrial Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 13: Endometrial Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 14: Endometrial Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010
Figure 15: Endometrial Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017
Figure 16: Endometrial Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 17: Endometrial Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 18: Opportunity and Unmet Need in the Endometrial Cancer Therapeutics Market, 2010
Figure 19: Endometrial Cancer Therapeutics – Strategic Competitor Assessment, 2011
Figure 20: Endometrial Cancer Therapeutics – Pipeline by Phase of Clinical Development, 2011
Figure 21: Endometrial Cancer Therapeutics – Technology Trends Analytics Framework, 2011
Figure 22: Endometrial Cancer Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 23: Endometrial Cancer Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 24: Endometrial Cancer Therapeutics – Clinical Trials by Country, 2011
Figure 25: Endometrial Cancer Therapeutics – Clinical Trials by Phase, 2011
Figure 26: Endometrial Cancer Therapeutics – Clinical Trials by Status, 2011
Figure 27: Endometrial Cancer Therapeutics – Overall Sponsors, 2011
Figure 28: Endometrial Cancer Therapeutics – Prominent Sponsors, 2011
Figure 29: Endometrial Cancer Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 30: Endometrial Cancer Therapeutics, Drivers and Restraints, 2011
Figure 31: Endometrial Cancer Therapeutics – Implications for Future Market Competition, 2011
Figure 32: Endometrial Cancer Therapeutics – Future Players, 2011
Figure 33: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Bristol-Myers Squibb Company
AEterna Zentaris Inc
Ariad Pharmaceuticals Inc
Eisai Co., Ltd
EntreMed, Inc.
Exelixis, Inc.
Ipsen S.A. (Ipsen)
Merck & Co
Novartis AG
PharmaMar, S.A (Subsidiary of Zeltia, S.A.)
Sanofi Skip to top